CpG used as an adjuvant for an adenovirus-based Venezuelan equine encephalitis virus vaccine increases the immune response to the vector, but not to the transgene product

Viral Immunology

Volumn 21, Issue 4, 2008, Pages 451-457

  Perkins, Stuart D ^a   Williams, Amanda J ^a   O'Brien, Lyn M ^a   Laws, Thomas R ^a   Phillpotts, Robert J ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADJUVANT; ANTIBODY; ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GENE PRODUCT; UNCLASSIFIED DRUG; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS VACCINE; VIRUS VACCINE;

AEROSOL; ALPHA VIRUS; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BAGG ALBINO MOUSE; BIOLOGICAL WARFARE; CONTROLLED STUDY; DRUG EFFICACY; ENCEPHALOMYELITIS; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; TRANSGENE; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; ENCEPHALOMYELITIS, VENEZUELAN EQUINE; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; TRANSGENES; VIRAL VACCINES;

ADENOVIRIDAE; ALPHAVIRUS; MUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 58149252368     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2008.0052     Document Type: Article

References (69)

1. Alibek K: The Emerging BW Threat: Lessons from the Russian Offensive BW R&D Program, 1945 to 1992. Maxwell AFB, Alabama, 1999.
2. Andersen JM, Al-Khairy D, and Ingalls RR: Innate immunity at the mucosal surface: Role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod 2006;74:824-831.
3. Barouch DH, Mckay PF, Sumida SM, et al.: Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J Virol 2003;77:8729-8735.
4. Barouch DH, Pau MG, Custers JHHV, et al.: Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004;172:6290-6297.
5. Belyakov IM, Moss B, Strober W, and Berzofsky JA: Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA 1999;96:4512-4517.
6. Belyakov IM, Earl P, Dzutsev A, et al.: Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 2003;100:9458-9463.
7. + T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host. J Immunol 2006;177:6336-6343.
8. Bennett AM, Elvin SJ, Wright AJ, Jones SM, and Phillpotts RJ: An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine 2000;19:337-347.
9. Bos R, Van Duikeren S, Van Hall T, et al.: Characterization of antigen-specific immune responses induced by Canary-pox virus vaccines. J Immunol 2007;179:6115-6122.
10. Casimiro DR, Chen L, Fu TM, et al.: Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003;77:6305-6313.
11. Cooper CL, Davis HL, Morris ML, et al.: CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B® HBV vaccine in healthy adults: A double-blind phase I/II study. J Clin Immunol 2004;24:693-701.
12. Cooper CL, Davis HL, Morris ML, et al.: Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 2004;22:3136-3143.
13. Cottalorda A, Verschelde C, Marcais A, et al.: TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur J Immunol 2006;36:1684-1693.
14. de Mucha-Macias J, and Sanchez-Spindola I: Two human cases of laboratory infection with Mucambo virus. Am J Trop Med Hyg 1965;14:475-478.
15. Dietz WHJ, Peralta PH, and Johnson KM: Ten clinical cases of human infection with Venezuelan equine encephalomyelitis virus, subtype I-D. Am J Trop Med Hyg 1979;28:329-334.
16. Elvin SJ, Bennett AM, and Phillpotts RJ: Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus. J Med Virol 2002;67:384-393.
17. Griffin D, Levine B, Tyor W, Ubol S, and Despres P: The role of antibody in recovery from alphavirus encephalitis. Immunological Rev 1997;159:155-161.
18. Gu M, Hine PM, James Jackson W, Giri L, and Nabors GS: Increased potency of BioThrax® anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine 2007;25:526-534.
19. Guyton AC: Measurement of the respiratory volume of laboratory animals. Am J Physiol 1947;150:70-77.
20. Halperin SA, Dobson S, McNeil S, et al.: Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine 2006;24:20-26.
21. Halperin SA, Van Nest G, Smith B, Simin A, Whiley H, and Eiden JJ: A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant. Vaccine 2003;21:2461-2467.
22. Hart M, Caswell-Stephan K, Bakken R, et al.: Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 2000;18:3067-3075.
23. Hart MK, Caswell-Stephan K, Bakken R, et al.: Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 2000;18:3067-3075.
24. Hart MK, Lind C, Bakken R, Robertson M, Tammariello R, and Ludwig GV: Onset and duration of protective immunity to IA/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice. Vaccine 2001;20:616-622.
25. Hawley RJ, and Eitzen EM, Jr.: Biological weapons - a primer for microbiologists. Annu Rev Microbiol 2001;55:235-253.
26. Hernandez HM, Figueredo M, Garrido N, Sanchez L, and Sarracent J: Intranasal immunisation with a 62 kDa proteinase combined with cholera toxin or CpG adjuvant protects against Trichomonas vaginalis genital tract infections in mice. Int J Parasitol 2005;35:1333-1337.
27. Hilleman MR: Overview: cause and prevention in biowarfare and bioterrorism. Vaccine 2002;20:3055-3067.
28. Horner AA, Ronaghy A, Cheng PM, et al.: Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol 1998;190:77-82.
29. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-4537.
30. Johnson KM, and Martin DH: Venezuelan equine encephalitis. Adv Vet Sci Comp Med 1974;18:79-116.
31. Jones LD, Bennett AM, Moss SR, Gould EA, and Phillpotts RJ: Cytotoxic T-cell activity is not detectable in Venezuelan equine encephalitis virus-infected mice. Virus Res 2003;91:255-259.
32. Jurk M, and Vollmer J: Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 2007;21:387-401.
33. Karan D, Krieg AM, and Lubaroff DM: Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer 2007;121:1520-1528.
34. KassEisler A, FalckPedersen E, Elfenbein DH, Alvira M, Buttrick PM, and Leinwand LA: The impact of developmental stage, route of administration and the immune-system on adenovirus-mediated gene-transfer. Gene Ther 1994;1:395-402.
35. KassEisler A, Leinwand L, Gall J, Bloom B, and FalckPedersen E: Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 1996;3:154-162.
36. Klietmann WF, and Ruoff KL: Bioterrorism: implications for the clinical microbiologist. Clin Microbiol Rev 2001;14:364-381.
37. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-760.
38. Krieg AM, Yi AK, Matson S, et al.: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374:546-549.
39. Lemckert AAC, Sumida SM, Holterman L, et al.: Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-Ad5 immunity. J Virol 2005;79:9694-9701.
40. Lubaroff DM, Karan D, Andrews MP, et al.: Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. Vaccine 2006;24:6155-6162.
41. Mansson A, Adner M, and Cardell L: Toll-like receptors in cellular subsets of human tonsil T cells: altered expression during recurrent tonsillitis. Respir Res 2006;7:36.
42. McCluskie MJ, and Davis HL: CpG DNA as mucosal adjuvant. Vaccine 1999;18:231-237.
43. Moldoveanu Z, Love-Homan L, Huang WQ, and Krieg AM: CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998;16:1216-1224.
44. Natuk RJ, Lubeck MD, Chanda PK, et al.: Immunogenicity of recombinant human adenovirus human-immunodeficiency-virus vaccines in chimpanzees. AIDS Res Hum Retroviruses 1993;9:395-404.
45. Paessler S, Yun NE, Judy BM, et al.: Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection. Virology 2007;367:307-323.
46. Perkins SD, O'Brien LM, and Phillpotts RJ: Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination. Vaccine 2006;24:3440-3445.
47. Phillpotts RJ, Brooks TJ, and Cox CS: A simple device for the exposure of animals to infectious microorganisms by the airborne route. Epidemiol Infect 1997;118:71-75.
48. Phillpotts RJ, O'Brien L, Appleton RE, Carr S, and Bennett A: Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. Vaccine 2005;23:1615-1623.
49. Phillpotts RJ, Wright A. TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus. Vaccine 1999;17:982-988.
50. Rao V, Hinz ME, Roberts BA, and Fine D: Toxicity assessment of Venezuelan equine encephalitis virus vaccine candidate strain v3526. Vaccine 2006;24:1710-1715.
51. Reed DS, Lind CM, Lackemeyer MG, Sullivan LJ, Pratt WD, and Parker MD: Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus. Vaccine 2005;23:3139-3147.
52. Rosas CT, Paessler S, Ni HL, and Osterrieder N: Protection of mice by equine herpesvirus type 1-based experimental vaccine against lethal Venezuelan equine encephalitis virus infection in the absence of neutralizing antibodies. Am J Trop Med Hyg 2008;78:83-92.
53. Salucci V, Mennuni C, Calvaruso F, et al.: CD8(+) T-cell tolerance can be broken by an adenoviral vaccine while CD4(+) T-cell tolerance is broken by additional co-administration of a toll-like receptor ligand. Scand J Immunol 2006;63:35-41.
54. Schmaljohn AL, Johnson ED, Dalrymple JM, and Cole GA: Non-neutralizing monoclonal-antibodies can prevent lethal alphavirus encephalitis. Nature 1982;297:70-72.
55. Shiver JW, and Emini EA: Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Ann Rev Med 2004;55:355-372.
56. Speiser DE, Lienard D, Rufer N, et al.: Rapid and strong human CD8(+) T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005;115:739-746.
57. Stockholm International Peace Research Institute: The problem of chemical and biological warfare, Vol. 2. CB Weapons Today. Almqvist and Wiksell, Stockholm, 1973.
58. Sumida SM, Truitt DM, Kishko MG, et al.: Neutralizing antibodies and CD8(+) T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 2004;78:2666-2673.
59. Takeshita S, Takeshita F, Haddad DE, Janabi N, and Klinman DM: Activation of microglia and astrocytes by CpG oligodeoxynucleotides. Neuroreport 2001;12:3029-3032.
60. Titball RW, and Williamson ED: Vaccine development for potential bioterrorism agents. Curr Drug Targets Infect Disord 2003;3:255-262.
61. Turell MJ, and Parker MD: Protection of hamsters by Venezuelan equine encephalitis virus candidate vaccine V3526 against lethal challenge by mosquito bite and intraperitoneal injection. Am J Trop Med Hyg 2008;78:328-332.
62. Van Kampen KR, Shi ZK, Gao P, et al.: Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 2005;23:1029-1036.
63. VanOosten RL, and Griffith TS: Activation of tumor-specific CD8(+) T cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy. Cancer Res 2007;67:11980-11990.
64. Vollmer J, Weeratna R, Payette P, et al.: Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol 2004;34:251-262.
65. Weaver SC, Ferro C, Barrera R, Boshell J, and Navarro JC: Venezuelan equine encephalitis. Annu Rev Entomol 2004;49:141-174.
66. Weeratna RD, McCluskie MJ, Xu Y, and Davis HL: CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000;18:1755-1762.
67. Wright AJ, and Phillpotts RJ: Humane endpoints are an objective measure of morbidity in Venezuelan encephalomyelitis virus infection of mice. Arch Virol 1998;143:1155-1162.
68. Wyatt LS, Earl PL, Eller LA, and Moss B: Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 2004;101:4590-4595.
69. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, and Ertl HCJ: Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 2003;77:10780-10789.